Home Parenteral Nutrition (HPN) has revolutionised the treatment of in
testinal failure. In Europe, incidences and prevalences are approximat
ely 2-3 patients/year/10(6) inhabitants. As in USA, cancer has become
the main Indication for HPN in Europe, while Crohn's disease represent
s 15% of the cases. The major cause of HPN-related morbidity remains c
atheter infection. Metabolic complications can occur in patients with
longterm HPN. In patients with non-malignant diseases, probability of
survival at 5 years is about 65%. Quality of life is considered very g
ood in about 60% of these cases. Prognosis of cancer patients is very
limited.